Influence of KRAS G13D mutations on outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy with or without cetuximab

被引：14
|
作者：
Tejpar, S.
Bokemeyer, C.
Celik, I.
Schlichting, M.
Sartorius, U.
Van Cutsem, E.
机构：
[1] Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium
[2] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany
[3] Merck KGaA, Darmstadt, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.3511
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3511
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Association of KRAS G13D Tumor Mutations With Outcome in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy With or Without Cetuximab
    Tejpar, Sabine
    Celik, Ilhan
    Schlichting, Michael
    Sartorius, Ute
    Bokemeyer, Carsten
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (29) : 3570 - 3577
  • [2] The role of the KRAS G13D mutation in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy plus cetuximab
    Tejpar, S.
    Bokemeyer, C.
    Celik, I.
    Schlichting, M.
    Van Cutsem, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [3] KRAS MUTATIONS AND OUTCOME IN PATIENTS WITH METASTATIC COLORECTAL CANCER TREATED WITH FIRST-LINE CHEMOTHERAPY WITH OR WITHOUT CETUXIMAB
    Tejpar, Sabine
    Bokemeyer, Carsten
    Celik, Ilhan
    Schlichting, Michael
    Heeger, Steffen
    Van Cutsem, Eric
    ANNALS OF ONCOLOGY, 2011, 22 : v16 - v17
  • [4] Association KRAS G13D Tumor Mutated Outcome in Patients with Chemotherapy Refractory Metastatic Colorectal Cancer Treated with Cetuximab
    Tural, Deniz
    Selcukbiricik, Fatih
    Erdamar, Sibel
    Ozkurt, Canan Unlu
    Yanmaz, Teoman
    Mandel, Nil Molinas
    Serdengecti, Suheyla
    HEPATO-GASTROENTEROLOGY, 2013, 60 (125) : 1035 - 1040
  • [5] KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience
    Van Cutsem, E.
    Lang, I.
    D'haens, G.
    Moiseyenko, V.
    Zaluski, J.
    Folprecht, G.
    Tejpar, S.
    Kisker, O.
    Stroh, C.
    Rougier, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [6] PHASE II STUDY OF SINGLE AGENT CETUXIMAB IN KRAS G13D MUTANT METASTATIC COLORECTAL CANCER (MCRC)
    Schirripa, M.
    Lonardi, S.
    Cremolini, C.
    Loupakis, F.
    Salvatore, L.
    Bergamo, F.
    Antoniotti, C.
    Roma, A.
    Bertorelle, R.
    Marmorino, F.
    Rossini, D.
    Pasquini, G.
    Zoratto, F.
    Masi, G.
    Zagonel, V.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2014, 25 : 7 - 7
  • [7] Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer (mCRC).
    Schirripa, Marta
    Lonardi, Sara
    Cremolini, Chiara
    Loupakis, Fotios
    Salvatore, Lisa
    Bergamo, Francesca
    Antoniotti, Carlotta
    Roma, Anna
    Bertorelle, Roberta
    Masi, Gianluca
    Marmorino, Federica
    Rossini, Daniele
    Pasquini, Giulia
    Zoratto, Federica
    Zagonel, Vittorina
    Falcone, Alfredo
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience
    Bokemeyer, C.
    Bondarenko, I.
    Hartmann, J. T.
    De Braud, F. G.
    Volovat, C.
    Nippgen, J.
    Stroh, C.
    Celik, I.
    Koralewski, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] KRAS status and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFOX chemotherapy
    Sharma, Neelesh
    Saifo, Maher
    Tamaskar, Ila R.
    Bhuvaneswari, Ramkumar
    Mashtare, Terry
    Fakih, Marwan
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2010, 1 (02) : 90 - 96
  • [10] Influence of KRAS p.G13D Mutation in Patients With Metastatic Colorectal Cancer Treated With Cetuximab
    Gajate, Pablo
    Sastre, Javier
    Bando, Inmaculada
    Alonso, Teresa
    Cillero, Lourdes
    Sanz, Julian
    Caldes, Trinidad
    Diaz-Rubio, Eduardo
    CLINICAL COLORECTAL CANCER, 2012, 11 (04) : 291 - 296
12345